Jennifer King
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Jennifer King
Non-Executive Director / Tryptamine Therapeutics
Dr Jennifer King has over 20 years of operating experience in the biopharmaceutical industry.
She is a principal of King BioConsulting which provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications.
From 2015 to 2019 Dr King was with Intellia Therapeutics, a CRISPR Cas9 genome editing startup, as senior vice president for business development. She founded and grew its business development and new product commercialization groups; and was responsible for accessing external sources of innovation, establishing the company’s key industry partnerships, overseeing the alliance management activities for these partnerships, and developing commercial strategies and frameworks for the company’s genome editing platform. Prior to Intellia, Dr King was the global brand director and senior director of business development at Shire (now Takeda), and held a variety of commercial roles in at Millennium Pharmaceuticals including as product manager for the US launch of VELCADE®.
Dr King holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology, a PhD in Developmental Biology at the Stanford University School of Medicine, and an MBA from Northeastern University.
She is a principal of King BioConsulting which provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications.
From 2015 to 2019 Dr King was with Intellia Therapeutics, a CRISPR Cas9 genome editing startup, as senior vice president for business development. She founded and grew its business development and new product commercialization groups; and was responsible for accessing external sources of innovation, establishing the company’s key industry partnerships, overseeing the alliance management activities for these partnerships, and developing commercial strategies and frameworks for the company’s genome editing platform. Prior to Intellia, Dr King was the global brand director and senior director of business development at Shire (now Takeda), and held a variety of commercial roles in at Millennium Pharmaceuticals including as product manager for the US launch of VELCADE®.
Dr King holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology, a PhD in Developmental Biology at the Stanford University School of Medicine, and an MBA from Northeastern University.
Lists and Charts
Total Shareholder Return as at 29/11/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 28th | Tryptamine Therapeutics | 301% | -34% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Tryptamine Therapeutics | $1.1m |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEW ROLE: Non-Executive Director, Tryptamine Therapeutics | 01 Sep 2021 |
